Reviewed By
Overview
SCIENTIFIC SCORE
Questionable
Based on 27 Researches
6.3
USERS' SCORE
Moderately Good
Based on 6 Reviews
7.7
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin D3 (as Cholecalciferol) (from Lanolin)
50 mcg (2,000 IU)
250%
Top Medical Research Studies
9
We investigated the influence of calcitriol, the active form of vitamin D, on experimental autoimmune encephalomyelitis (EAE), an animal model akin to multiple sclerosis. Our study involved twenty-eight mice divided into four groups, allowing us to compare outcomes between those with and without EAE, as well as those receiving calcitriol treatment.
We found that, in mice with EAE, inflammation indicators such as interleukin-17 (IL-17) significantly increased, while transforming growth factor beta (TGF-β) levels decreased compared to healthy controls. Upon treating the EAE group with calcitriol, we observed a reversal of these changes, suggesting a substantial immunomodulatory effect, which eased symptoms typically associated with EAE.
Notably, we also noticed that calcitriol enhanced gene expression for interleukin-9 (IL-9) in both healthy and EAE mice. Overall, our findings support the notion that calcitriol holds promise as a potential treatment to alleviate the symptoms of multiple sclerosis through its anti-inflammatory properties.
We found that, in mice with EAE, inflammation indicators such as interleukin-17 (IL-17) significantly increased, while transforming growth factor beta (TGF-β) levels decreased compared to healthy controls. Upon treating the EAE group with calcitriol, we observed a reversal of these changes, suggesting a substantial immunomodulatory effect, which eased symptoms typically associated with EAE.
Notably, we also noticed that calcitriol enhanced gene expression for interleukin-9 (IL-9) in both healthy and EAE mice. Overall, our findings support the notion that calcitriol holds promise as a potential treatment to alleviate the symptoms of multiple sclerosis through its anti-inflammatory properties.
Read More
8
We explored how vitamin D (VitD) levels relate to the activity of multiple sclerosis (MS) in patients about to start treatment. By measuring serum levels of a specific form of VitD in 230 untreated individuals with relapsing-remitting MS, we aimed to see if higher VitD could reduce disease activity over the subsequent two years.
Our findings revealed that lower VitD levels were linked to a greater likelihood of disease activity, specifically noting that patients with VitD levels below 20 ng/mL faced more than double the risk of experiencing such activity. Interestingly, we found that genetic factors also played a role; those with a genetic predisposition to higher VitD levels were more likely to have a delayed onset of MS and a better chance of maintaining a status known as No-Evidence of Disease Activity-3 (NEDA-3).
Through further analysis using Mendelian randomization, we confirmed that there is a causal relationship between VitD levels and disease activity in MS. This research highlights the potential benefits of monitoring and possibly supplementing VitD for patients, prompting a greater interest in lifestyle changes that could help manage the disease.
Our findings revealed that lower VitD levels were linked to a greater likelihood of disease activity, specifically noting that patients with VitD levels below 20 ng/mL faced more than double the risk of experiencing such activity. Interestingly, we found that genetic factors also played a role; those with a genetic predisposition to higher VitD levels were more likely to have a delayed onset of MS and a better chance of maintaining a status known as No-Evidence of Disease Activity-3 (NEDA-3).
Through further analysis using Mendelian randomization, we confirmed that there is a causal relationship between VitD levels and disease activity in MS. This research highlights the potential benefits of monitoring and possibly supplementing VitD for patients, prompting a greater interest in lifestyle changes that could help manage the disease.
Read More
8
Vitamin D3 influences MS immune response
We conducted a thorough investigation into the potential benefits of vitamin D3 supplementation for individuals who have experienced a first demyelinating event, which can be an early indication of multiple sclerosis (MS). Our study was a part of the PrevANZ trial and involved randomizing participants to receive varying doses of vitamin D—1000, 5000, or 10,000 international units—or a placebo, over a period of 12 weeks.
We focused on how these vitamin D3 supplements affected the gene expression of immune cells. After analyzing blood samples from 55 participants both at the beginning and end of the study, we observed that higher doses of vitamin D significantly influenced immune cell activity. Specifically, we found pathways linked to antigen presentation and viral responses became more active, while pathways associated with energy production and certain immune signals, like tumor necrosis factor-alpha and interleukin-17, were less active.
Overall, the results indicate that vitamin D3 supplementation can lead to an anti-inflammatory shift in immune gene expression, suggesting a potential protective role in the development of MS. This study supports the hypothesis that vitamin D3 could be an effective strategy, showing a dose-dependent relationship in immune response modulation.
We focused on how these vitamin D3 supplements affected the gene expression of immune cells. After analyzing blood samples from 55 participants both at the beginning and end of the study, we observed that higher doses of vitamin D significantly influenced immune cell activity. Specifically, we found pathways linked to antigen presentation and viral responses became more active, while pathways associated with energy production and certain immune signals, like tumor necrosis factor-alpha and interleukin-17, were less active.
Overall, the results indicate that vitamin D3 supplementation can lead to an anti-inflammatory shift in immune gene expression, suggesting a potential protective role in the development of MS. This study supports the hypothesis that vitamin D3 could be an effective strategy, showing a dose-dependent relationship in immune response modulation.
Read More
Most Useful Reviews
6
Boosts immunity
15 people found this helpful
Solar cell D3 is essential for everyone. It enhances immunity, reduces the risk of viral diseases, and is vital for various bodily functions. In our area, sunlight is limited, making D3 supplementation crucial. I prefer NOW Vitamin D3, as it offers excellent quality at a reasonable price.
Read More
6
Immunity enhancement
8 people found this helpful
D3 is crucial for the immune system and reduces viral disease risks. It's synthesised in sunlight, so supplementation is important, especially during winter. I recommend NOW Vitamin D3 for its quality and value.
Read More
7.5
Supports brain health
Over 50? Take vitamin D3! It's excellent for bone health and prevents serious conditions like multiple sclerosis. The dosage works quickly, and I noticed positive effects soon after starting. Recommended for improving health!
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 27 Researches
6.3
- All Researches
9
We evaluated how vitamin D affects multiple sclerosis (MS) by exploring the properties of immune cells in treatment-naive MS patients compared to healthy donors. Our research revealed that patients’ immune cells had heightened proinflammatory features, particularly related to key pathways involving the aryl hydrocarbon receptor (AhR) and NF-κB. This imbalance may contribute to the difficulties in managing MS effectively.
We discovered that dendritic cells derived from MS patients showed reduced tolerogenic capabilities. However, when we applied vitamin D3 and directly activated the AhR, we were able to restore these properties. Furthermore, combining vitamin D3 with a drug known as dimethyl fumarate (DMF) not only enhanced the tolerogenic effects but also provided a more effective treatment option in experiments on mice.
Our findings suggest that a combined therapy utilizing DMF and vitamin D3-tolerogenic dendritic cells has great potential in improving treatment for MS. However, it is worth noting that the analysis focuses on the combination therapy rather than isolating the effects of vitamin D alone.
We discovered that dendritic cells derived from MS patients showed reduced tolerogenic capabilities. However, when we applied vitamin D3 and directly activated the AhR, we were able to restore these properties. Furthermore, combining vitamin D3 with a drug known as dimethyl fumarate (DMF) not only enhanced the tolerogenic effects but also provided a more effective treatment option in experiments on mice.
Our findings suggest that a combined therapy utilizing DMF and vitamin D3-tolerogenic dendritic cells has great potential in improving treatment for MS. However, it is worth noting that the analysis focuses on the combination therapy rather than isolating the effects of vitamin D alone.
Read More
9
We investigated the influence of calcitriol, the active form of vitamin D, on experimental autoimmune encephalomyelitis (EAE), an animal model akin to multiple sclerosis. Our study involved twenty-eight mice divided into four groups, allowing us to compare outcomes between those with and without EAE, as well as those receiving calcitriol treatment.
We found that, in mice with EAE, inflammation indicators such as interleukin-17 (IL-17) significantly increased, while transforming growth factor beta (TGF-β) levels decreased compared to healthy controls. Upon treating the EAE group with calcitriol, we observed a reversal of these changes, suggesting a substantial immunomodulatory effect, which eased symptoms typically associated with EAE.
Notably, we also noticed that calcitriol enhanced gene expression for interleukin-9 (IL-9) in both healthy and EAE mice. Overall, our findings support the notion that calcitriol holds promise as a potential treatment to alleviate the symptoms of multiple sclerosis through its anti-inflammatory properties.
We found that, in mice with EAE, inflammation indicators such as interleukin-17 (IL-17) significantly increased, while transforming growth factor beta (TGF-β) levels decreased compared to healthy controls. Upon treating the EAE group with calcitriol, we observed a reversal of these changes, suggesting a substantial immunomodulatory effect, which eased symptoms typically associated with EAE.
Notably, we also noticed that calcitriol enhanced gene expression for interleukin-9 (IL-9) in both healthy and EAE mice. Overall, our findings support the notion that calcitriol holds promise as a potential treatment to alleviate the symptoms of multiple sclerosis through its anti-inflammatory properties.
Read More
9
We explored the effects of vitamin D3 on multiple sclerosis (MS) by examining its role in regulating a specific lipid called Sphingosine-1-phosphate (S1P), which is known to contribute to neuroinflammation and the progression of MS. In a series of carefully designed experiments, we looked at both the EAE model in rats, which mimics MS, and PC12 cells to understand how vitamin D3 may offer protective benefits against cellular damage.
Our findings indicated that vitamin D3 could alleviate symptoms of EAE in rats and reduce the severity of their condition. We observed that it also inhibited the expression of SphK1, which is responsible for producing S1P, leading to lower levels of this inflammatory mediator. In the laboratory environment, vitamin D3 significantly reduced cell death induced by S1P in PC12 cells, showing an improvement in cell attachment quality and overall health.
Additionally, vitamin D3 appeared to block pathways that are known to lead to inflammation and cell death. We noticed reductions in certain cytokines and apoptosis markers, which are associated with inflammatory responses. There was also an increase in a protein linked to nerve cell protection, suggesting vitamin D3 has multiple mechanisms through which it operates.
In summary, our research supports the idea that vitamin D3 has a protective effect against MS by lowering S1P levels and influencing several related pathways. This opens up promising avenues for vitamin D3 to be considered in combination therapies aimed at treating this challenging condition.
Our findings indicated that vitamin D3 could alleviate symptoms of EAE in rats and reduce the severity of their condition. We observed that it also inhibited the expression of SphK1, which is responsible for producing S1P, leading to lower levels of this inflammatory mediator. In the laboratory environment, vitamin D3 significantly reduced cell death induced by S1P in PC12 cells, showing an improvement in cell attachment quality and overall health.
Additionally, vitamin D3 appeared to block pathways that are known to lead to inflammation and cell death. We noticed reductions in certain cytokines and apoptosis markers, which are associated with inflammatory responses. There was also an increase in a protein linked to nerve cell protection, suggesting vitamin D3 has multiple mechanisms through which it operates.
In summary, our research supports the idea that vitamin D3 has a protective effect against MS by lowering S1P levels and influencing several related pathways. This opens up promising avenues for vitamin D3 to be considered in combination therapies aimed at treating this challenging condition.
Read More
8
We explored the potential impact of Vitamin D supplementation on patients newly diagnosed with Multiple Sclerosis (MS). Our study involved 16 drug-naïve patients who were monitored over a year. We measured the levels of 25-hydroxy-vitamin D in their blood and evaluated how this vitamin affects the balance between pro-inflammatory and anti-inflammatory cytokines, which play significant roles in MS.
Our findings showed that these patients initially had low vitamin D levels and high levels of pro-inflammatory cytokines. Over the course of the study, participants who received vitamin D supplementation demonstrated a notable decrease in pro-inflammatory cytokine levels. Additionally, the ratio of pro-inflammatory to anti-inflammatory cytokines improved, suggesting that vitamin D may help shift the immune response towards a more protective profile.
Interestingly, while some patients also received immunotherapy, our data indicated that Vitamin D supplementation might independently contribute to better immune regulation. Patients with higher pro-inflammatory cytokine ratios appeared more susceptible to relapses, emphasizing the potential role of Vitamin D in managing MS symptoms.
This research supports the idea that having adequate levels of Vitamin D could be vital for those facing MS, as it may offer a protective mechanism through improving immune responses. Ultimately, vitamin D supplementation could be an essential component of a comprehensive treatment plan for MS patients.
Our findings showed that these patients initially had low vitamin D levels and high levels of pro-inflammatory cytokines. Over the course of the study, participants who received vitamin D supplementation demonstrated a notable decrease in pro-inflammatory cytokine levels. Additionally, the ratio of pro-inflammatory to anti-inflammatory cytokines improved, suggesting that vitamin D may help shift the immune response towards a more protective profile.
Interestingly, while some patients also received immunotherapy, our data indicated that Vitamin D supplementation might independently contribute to better immune regulation. Patients with higher pro-inflammatory cytokine ratios appeared more susceptible to relapses, emphasizing the potential role of Vitamin D in managing MS symptoms.
This research supports the idea that having adequate levels of Vitamin D could be vital for those facing MS, as it may offer a protective mechanism through improving immune responses. Ultimately, vitamin D supplementation could be an essential component of a comprehensive treatment plan for MS patients.
Read More
8
We investigated how glucagon-like peptide-1 agonists (GLP-1s) impact people with multiple sclerosis (MS), particularly focusing on weight loss and vitamin D levels. Our research examined individuals with MS who used GLP-1 medications over an extended period from 2006 to 2024.
The findings were promising. We observed that after initiating GLP-1 treatment, participants experienced a significant decrease in body mass index (BMI) by an average of 3.7%. Moreover, there was an increase in vitamin D levels, with an average rise of 8.1 ng/mL. However, there were no notable changes in disability status or walking speed.
Importantly, we found that patients did not experience any hospitalizations or deaths during the study period following GLP-1 usage. This suggests that GLP-1 medications are not only safe for people with MS but also effective in boosting vitamin D levels, which may play a role in managing MS symptoms.
The findings were promising. We observed that after initiating GLP-1 treatment, participants experienced a significant decrease in body mass index (BMI) by an average of 3.7%. Moreover, there was an increase in vitamin D levels, with an average rise of 8.1 ng/mL. However, there were no notable changes in disability status or walking speed.
Importantly, we found that patients did not experience any hospitalizations or deaths during the study period following GLP-1 usage. This suggests that GLP-1 medications are not only safe for people with MS but also effective in boosting vitamin D levels, which may play a role in managing MS symptoms.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 6 Reviews
7.7
- All Reviews
- Positive Reviews
- Negative Reviews
6
Boosts immunity
15 people found this helpful
Solar cell D3 is essential for everyone. It enhances immunity, reduces the risk of viral diseases, and is vital for various bodily functions. In our area, sunlight is limited, making D3 supplementation crucial. I prefer NOW Vitamin D3, as it offers excellent quality at a reasonable price.
Read More
6
Immunity enhancement
8 people found this helpful
D3 is crucial for the immune system and reduces viral disease risks. It's synthesised in sunlight, so supplementation is important, especially during winter. I recommend NOW Vitamin D3 for its quality and value.
Read More
7.5
Supports brain health
Over 50? Take vitamin D3! It's excellent for bone health and prevents serious conditions like multiple sclerosis. The dosage works quickly, and I noticed positive effects soon after starting. Recommended for improving health!
Read More
6
Multiple sclerosis focus
At 23, I was diagnosed with multiple sclerosis. I began exploring diets and vitamins, realising D3's importance for managing autoimmune diseases. Regularly testing my vitamin D levels is crucial. I recommend D3 especially in winter due to limited sunlight.
Read More
6
Reduces disease risks
1 people found this helpful
Vitamin D3, known as the "solar cell", regulates immunity, reduces the risk of multiple sclerosis, and supports overall health. It’s vital for bones and essential in preventing various diseases.
Read More
Frequently Asked Questions
7.5
Supports brain health
Over 50? Take vitamin D3! It's excellent for bone health and prevents serious conditions like multiple sclerosis. The dosage works quickly, and I noticed positive effects soon after starting. Recommended for improving health!
6
Multiple sclerosis focus
At 23, I was diagnosed with multiple sclerosis. I began exploring diets and vitamins, realising D3's importance for managing autoimmune diseases. Regularly testing my vitamin D levels is crucial. I recommend D3 especially in winter due to limited sunlight.
6
Boosts immunity
15 people found this helpful
Solar cell D3 is essential for everyone. It enhances immunity, reduces the risk of viral diseases, and is vital for various bodily functions. In our area, sunlight is limited, making D3 supplementation crucial. I prefer NOW Vitamin D3, as it offers excellent quality at a reasonable price.
6
Reduces disease risks
1 people found this helpful
Vitamin D3, known as the "solar cell", regulates immunity, reduces the risk of multiple sclerosis, and supports overall health. It’s vital for bones and essential in preventing various diseases.
7.5
Disease prevention
Insufficient vitamin D can lead to chronic illnesses like multiple sclerosis and cancer. I take D3 regularly, with higher doses in winter to maintain my health and prevent long-term issues.
6
Immunity enhancement
8 people found this helpful
D3 is crucial for the immune system and reduces viral disease risks. It's synthesised in sunlight, so supplementation is important, especially during winter. I recommend NOW Vitamin D3 for its quality and value.
8
We explored the potential impact of Vitamin D supplementation on patients newly diagnosed with Multiple Sclerosis (MS). Our study involved 16 drug-naïve patients who were monitored over a year. We measured the levels of 25-hydroxy-vitamin D in their blood and evaluated how this vitamin affects the balance between pro-inflammatory and anti-inflammatory cytokines, which play significant roles in MS.
Our findings showed that these patients initially had low vitamin D levels and high levels of pro-inflammatory cytokines. Over the course of the study, participants who received vitamin D supplementation demonstrated a notable decrease in pro-inflammatory cytokine levels. Additionally, the ratio of pro-inflammatory to anti-inflammatory cytokines improved, suggesting that vitamin D may help shift the immune response towards a more protective profile.
Interestingly, while some patients also received immunotherapy, our data indicated that Vitamin D supplementation might independently contribute to better immune regulation. Patients with higher pro-inflammatory cytokine ratios appeared more susceptible to relapses, emphasizing the potential role of Vitamin D in managing MS symptoms.
This research supports the idea that having adequate levels of Vitamin D could be vital for those facing MS, as it may offer a protective mechanism through improving immune responses. Ultimately, vitamin D supplementation could be an essential component of a comprehensive treatment plan for MS patients.
Our findings showed that these patients initially had low vitamin D levels and high levels of pro-inflammatory cytokines. Over the course of the study, participants who received vitamin D supplementation demonstrated a notable decrease in pro-inflammatory cytokine levels. Additionally, the ratio of pro-inflammatory to anti-inflammatory cytokines improved, suggesting that vitamin D may help shift the immune response towards a more protective profile.
Interestingly, while some patients also received immunotherapy, our data indicated that Vitamin D supplementation might independently contribute to better immune regulation. Patients with higher pro-inflammatory cytokine ratios appeared more susceptible to relapses, emphasizing the potential role of Vitamin D in managing MS symptoms.
This research supports the idea that having adequate levels of Vitamin D could be vital for those facing MS, as it may offer a protective mechanism through improving immune responses. Ultimately, vitamin D supplementation could be an essential component of a comprehensive treatment plan for MS patients.
8
We investigated how glucagon-like peptide-1 agonists (GLP-1s) impact people with multiple sclerosis (MS), particularly focusing on weight loss and vitamin D levels. Our research examined individuals with MS who used GLP-1 medications over an extended period from 2006 to 2024.
The findings were promising. We observed that after initiating GLP-1 treatment, participants experienced a significant decrease in body mass index (BMI) by an average of 3.7%. Moreover, there was an increase in vitamin D levels, with an average rise of 8.1 ng/mL. However, there were no notable changes in disability status or walking speed.
Importantly, we found that patients did not experience any hospitalizations or deaths during the study period following GLP-1 usage. This suggests that GLP-1 medications are not only safe for people with MS but also effective in boosting vitamin D levels, which may play a role in managing MS symptoms.
The findings were promising. We observed that after initiating GLP-1 treatment, participants experienced a significant decrease in body mass index (BMI) by an average of 3.7%. Moreover, there was an increase in vitamin D levels, with an average rise of 8.1 ng/mL. However, there were no notable changes in disability status or walking speed.
Importantly, we found that patients did not experience any hospitalizations or deaths during the study period following GLP-1 usage. This suggests that GLP-1 medications are not only safe for people with MS but also effective in boosting vitamin D levels, which may play a role in managing MS symptoms.
7
We delved into the connection between vitamin D deficiency and the risk of multiple sclerosis (MS), utilizing data from 14 case-control studies published between 2007 and 2021. This analysis encompassed over 4,000 individuals with MS and another 4,600 without the condition.
Our findings reveal that individuals who are vitamin D deficient have a 54% higher chance of developing MS compared to those with sufficient vitamin D levels. Interestingly, when we looked closer, we found that this increased risk was particularly pronounced in studies that did not include participants taking vitamin D supplements.
Conversely, studies that included participants taking vitamin D supplements showed no significant increase in MS risk. This suggests that while vitamin D deficiency is associated with a higher likelihood of developing MS, the role of vitamin D supplementation may alter this relationship.
Overall, it seems that maintaining adequate vitamin D levels could be a significant, modifiable factor in reducing the risk of MS. However, more research is needed to fully understand the impact of vitamin D treatments on those already diagnosed with MS.
Our findings reveal that individuals who are vitamin D deficient have a 54% higher chance of developing MS compared to those with sufficient vitamin D levels. Interestingly, when we looked closer, we found that this increased risk was particularly pronounced in studies that did not include participants taking vitamin D supplements.
Conversely, studies that included participants taking vitamin D supplements showed no significant increase in MS risk. This suggests that while vitamin D deficiency is associated with a higher likelihood of developing MS, the role of vitamin D supplementation may alter this relationship.
Overall, it seems that maintaining adequate vitamin D levels could be a significant, modifiable factor in reducing the risk of MS. However, more research is needed to fully understand the impact of vitamin D treatments on those already diagnosed with MS.
4
We explored the effectiveness of vitamin D supplements for improving symptoms and reducing relapses in patients with multiple sclerosis (MS). A systematic review was conducted using data from eight reputable databases, which culminated in the selection of 16 randomized controlled trials.
Each of these studies confirmed that vitamin D administration significantly boosted levels of serum 25(OH)D compared to placebos. Most of these studies also indicated improvements in magnetic resonance imaging (MRI) brain lesion markers, which suggests that vitamin D may have some positive effects related to brain health.
However, when it comes to other important aspects—such as relapse rates, fatigue, and disability levels—most studies did not find significant benefits from vitamin D treatment compared to placebo. While some indicators, like the quality of life reflected through transforming growth factor beta (TGF-β), showed improvements, overall, the findings regarding the effectiveness of vitamin D in treating MS symptoms and relapses remain inconclusive.
In summary, while vitamin D supplementation does seem to raise certain health markers, its role in effectively treating MS is still uncertain.
Each of these studies confirmed that vitamin D administration significantly boosted levels of serum 25(OH)D compared to placebos. Most of these studies also indicated improvements in magnetic resonance imaging (MRI) brain lesion markers, which suggests that vitamin D may have some positive effects related to brain health.
However, when it comes to other important aspects—such as relapse rates, fatigue, and disability levels—most studies did not find significant benefits from vitamin D treatment compared to placebo. While some indicators, like the quality of life reflected through transforming growth factor beta (TGF-β), showed improvements, overall, the findings regarding the effectiveness of vitamin D in treating MS symptoms and relapses remain inconclusive.
In summary, while vitamin D supplementation does seem to raise certain health markers, its role in effectively treating MS is still uncertain.
2
Vitamin D shows limited MS impact
We aimed to understand how high-dose vitamin D affects people with multiple sclerosis (MS) by analyzing various randomized controlled trials. Our search included databases like PubMed, Embase, and the Cochrane Library, where we identified nine studies involving 867 participants.
The findings revealed that vitamin D supplementation, despite its promise, did not significantly improve clinical outcomes in these individuals. Specifically, we observed no notable changes in measures like the Expanded Disability Status Scale (EDSS), annualized relapse rates (ARR), or the count of new T2 lesions at 6 to 24 months after treatment.
Although the reduction in new T2 lesions was not significant, it raises questions about potential long-term benefits that could emerge with continued research. Thus, while current evidence suggests that vitamin D supplementation alone may not enhance MS management, the topic certainly warrants further exploration.
The findings revealed that vitamin D supplementation, despite its promise, did not significantly improve clinical outcomes in these individuals. Specifically, we observed no notable changes in measures like the Expanded Disability Status Scale (EDSS), annualized relapse rates (ARR), or the count of new T2 lesions at 6 to 24 months after treatment.
Although the reduction in new T2 lesions was not significant, it raises questions about potential long-term benefits that could emerge with continued research. Thus, while current evidence suggests that vitamin D supplementation alone may not enhance MS management, the topic certainly warrants further exploration.
8
Vitamin D3 enhances T cell tolerance
We conducted an insightful exploration into how Vitamin D3, alongside other therapeutic factors, influences immune responses in individuals dealing with multiple sclerosis (MS). Our research investigated the effects of a specific peptide, MOG35-55, combined with mannan, in promoting tolerance among T cells—these being crucial in the context of autoimmune conditions like MS.
Our experiments involved developing different types of dendritic cells from the blood of both healthy individuals and MS patients. By exposing these cells to MOG35-55 and observing their interactions with T cells over multiple cycles, we noticed a remarkable shift in the immune environment. Particularly, the dendritic cells soaked in Vitamin D3 exhibited promising results in enhancing the tolerance of T cells, showing increased levels of specific markers associated with immune regulation.
What's noteworthy is that these Vitamin D3-treated dendritic cells led to the highest occurrence of T cells indicating active regulation and suppression of autoimmune responses. This finding suggests a potential path forward toward tailored therapies for MS that leverage the immune-modulatory properties of Vitamin D3.
In conclusion, while we observed the potential benefits of Vitamin D3 in this context, we must also highlight that its effect was part of a complex interplay with other factors. Our study lays the groundwork for developing personalized vaccines or treatments for multiple sclerosis, emphasizing the role of specific immune modulation.
Our experiments involved developing different types of dendritic cells from the blood of both healthy individuals and MS patients. By exposing these cells to MOG35-55 and observing their interactions with T cells over multiple cycles, we noticed a remarkable shift in the immune environment. Particularly, the dendritic cells soaked in Vitamin D3 exhibited promising results in enhancing the tolerance of T cells, showing increased levels of specific markers associated with immune regulation.
What's noteworthy is that these Vitamin D3-treated dendritic cells led to the highest occurrence of T cells indicating active regulation and suppression of autoimmune responses. This finding suggests a potential path forward toward tailored therapies for MS that leverage the immune-modulatory properties of Vitamin D3.
In conclusion, while we observed the potential benefits of Vitamin D3 in this context, we must also highlight that its effect was part of a complex interplay with other factors. Our study lays the groundwork for developing personalized vaccines or treatments for multiple sclerosis, emphasizing the role of specific immune modulation.
References
- Al-Shammri S, Chattopadhyay A, Raghupathy R. Vitamin D supplementation mediates a shift towards anti-inflammatory cytokine response in Multiple Sclerosis. Med Princ Pract. 2025. 10.1159/000544106
- Rasheed A, Khan G. Epstein-Barr virus, vitamin D and the immune response: connections with consequences for multiple sclerosis. Front Immunol. 2024;15:1503808. 10.3389/fimmu.2024.1503808
- Lis M, Niedziela N, Adamczyk-Zostawa J, Zalejska-Fiolka J, Szczygieł J, et al. Comparative Effects of Vitamin D Supplementation on Oxidative Stress in Relapsing-Remitting Multiple Sclerosis. Curr Issues Mol Biol. 2024;46:14119. 10.3390/cimb46120845
- Balshi A, Leuenberger G, Dempsey J, Baber U, Sloane JA. Glucagon-like peptide-1 agonist safety and efficacy in a multiple sclerosis cohort. Mult Scler Relat Disord. 2025;93:106229. 10.1016/j.msard.2024.106229
- Yu XH, Lu HM, Li J, Su MZ, Li XM, et al. Association between 25(OH) vitamin D and multiple sclerosis: cohort, shared genetics, and Causality. Nutr J. 2024;23:151. 10.1186/s12937-024-01059-4
- France-Ratcliffe M, Harrison SL, Verma LA, Abdul-Rahim AH, McCallum L, et al. Vitamin D and cardiovascular outcomes in multiple sclerosis. Mult Scler Relat Disord. 2024;92:106155. 10.1016/j.msard.2024.106155
- Niedziela N, Nowak-Kiczmer M, Malciene L, Stasiołek M, Niedziela JT, et al. Serum Vitamin D3 as a Potential Biomarker for Neuronal Damage in Smoldering Multiple Sclerosis. Int J Mol Sci. 2024;25. 10.3390/ijms251910502
- Gill A, Orji C, Reghefaoui M, Peresuodei TS, Thota P, et al. The Effectiveness of Vitamin D Intake in Improving Symptoms and Relapses of Multiple Sclerosis: A Systematic Review. Cureus. 2024;16:e68565. 10.7759/cureus.68565
- Fondelli F, Willemyns J, Domenech-Garcia R, Mansilla MJ, Godoy-Tena G, et al. Targeting aryl hydrocarbon receptor functionally restores tolerogenic dendritic cells derived from patients with multiple sclerosis. J Clin Invest. 2024;134. 10.1172/JCI178949
- Alelyani M, Gameraddin M, Alshahrani R, Alaslami W, Sarhan R, et al. Assessment of vitamin D status and associated risk factors in high-altitude populations affected by multiple sclerosis: A case-control study. Medicine (Baltimore). 2024;103:e38369. 10.1097/MD.0000000000038369
- Balasooriya NN, Elliott TM, Neale RE, Vasquez P, Comans T, et al. The association between vitamin D deficiency and multiple sclerosis: an updated systematic review and meta-analysis. Mult Scler Relat Disord. 2024;90:105804. 10.1016/j.msard.2024.105804
- Lis M, Niedziela N, Adamczyk-Zostawa J, Zalejska-Fiolka J, Błachut M, et al. Can Vitamin D Reduce Inflammation? The Influence of Supplementation on Selected Immunological Markers. Int J Mol Sci. 2024;25. 10.3390/ijms25147592
- Lis M, Niedziela N, Adamczyk-Zostawa J, Wierzbicki K, Czuba Z, et al. Can Vitamin D Supplementation Improve Inflammation in Relapsing-Remitting Multiple Sclerosis Patients?. Biomedicines. 2024;12. 10.3390/biomedicines12071580
- Giordano A, Clarelli F, Pignolet B, Mascia E, Sorosina M, et al. Vitamin D affects the risk of disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025;96:170. 10.1136/jnnp-2024-334062
- Rodi M, de Lastic AL, Panagoulias I, Aggeletopoulou I, Kelaidonis K, et al. Myelin Oligodendrocyte Glycoprotein (MOG)35-55 Mannan Conjugate Induces Human T-Cell Tolerance and Can Be Used as a Personalized Therapy for Multiple Sclerosis. Int J Mol Sci. 2024;25. 10.3390/ijms25116092
- Maghbooli Z, Shirvani A, Moghadasi AN, Varzandi T, Hamtaei Ghashti S, et al. Investigating the effects of 25-hydroxyvitamin D3 on clinical outcomes in multiple sclerosis patients: A randomized, double-blind clinical trial- a pilot study. Mult Scler Relat Disord. 2024;87:105673. 10.1016/j.msard.2024.105673
- Fasihi M, Samimi-Badabi M, Robat-Jazi B, Bitarafan S, Moghadasi AN, et al. Immunoregulatory Effects of the Active Form of Vitamin D (Calcitriol), Individually and in Combination with Curcumin, on Peripheral Blood Mononuclear Cells (PBMCs) of Multiple Sclerosis (MS) Patients. Antiinflamm Antiallergy Agents Med Chem. 2024;23:138. 10.2174/0118715230293847240314073359
- Yeh WZ, Gresle M, Lea R, Taylor B, Lucas RM, et al. The immune cell transcriptome is modulated by vitamin D supplementation in people with a first demyelinating event participating in a randomized placebo-controlled trial. Clin Immunol. 2024;262:110183. 10.1016/j.clim.2024.110183
- Qu F, Zhang M, Weinstock-Guttman B, Zivadinov R, Qu J, et al. An ultra-sensitive and high-throughput trapping-micro-LC-MS method for quantification of circulating vitamin D metabolites and application in multiple sclerosis patients. Sci Rep. 2024;14:5545. 10.1038/s41598-024-55939-0
- Mahler JV, Solti M, Apóstolos-Pereira SL, Adoni T, Silva GD, et al. Vitamin D as an add-on treatment for multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. Mult Scler Relat Disord. 2024;82:105433. 10.1016/j.msard.2024.105433
- Robat-Jazi B, Oraei M, Bitarafan S, Mesbah-Namin SA, Noori-Zadeh A, et al. Immunoregulatory Effect of Calcitriol on Experimental Autoimmune Encephalomyelitis (EAE) Mice. Iran J Allergy Asthma Immunol. 2023;22:452. 10.18502/ijaai.v22i5.13995
- Wang Z, Yi SY, Zhang YY, Wang YD, Chen HL, et al. The role of vitamin D through SphK1/S1P in the regulation of MS progression. J Steroid Biochem Mol Biol. 2024;236:106425. 10.1016/j.jsbmb.2023.106425
- Carlberg C, Mycko MP. Linking Mechanisms of Vitamin D Signaling with Multiple Sclerosis. Cells. 2023;12. 10.3390/cells12192391
- Sangha A, Quon M, Pfeffer G, Orton SM. The Role of Vitamin D in Neuroprotection in Multiple Sclerosis: An Update. Nutrients. 2023;15. 10.3390/nu15132978
- López-Muñoz P, Torres-Costoso AI, Fernández-Rodríguez R, Guzmán-Pavón MJ, de Arenas-Arroyo SN, et al. Effect of Vitamin D Supplementation on Fatigue in Multiple Sclerosis: A Systematic Review and Meta-Analysis. Nutrients. 2023;15. 10.3390/nu15132861
- Gselman S, Fabjan TH, Bizjak A, Potočnik U, Gorenjak M. Cholecalciferol Supplementation Induced Up-Regulation of Gene and Down-Regulated miR-155-5p Expression in Slovenian Patients with Multiple Sclerosis. Genes (Basel). 2023;14. 10.3390/genes14061237
- Essa SA, Elokda A, Mosaad D, Shendy W, Abdel-Nasser M, et al. Efficacy of ultraviolet B radiation versus vitamin D on postural control and cognitive functions in relapsing-remitting multiple sclerosis: A randomized controlled study. J Bodyw Mov Ther. 2023;35:49. 10.1016/j.jbmt.2023.04.069
